| 1.56 -0.06 (-3.7%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.22 | 1-year : | 4.18 |
| Resists | First : | 2.75 | Second : | 3.57 |
| Pivot price | 1.93  |
|||
| Supports | First : | 1.42 | Second : | 1.18 |
| MAs | MA(5) : | 1.73 |
MA(20) : | 2.19 |
| MA(100) : | 3.34 |
MA(250) : | 7.01 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 8.7 |
D(3) : | 11.6 |
| RSI | RSI(14): 38 |
|||
| 52-week | High : | 16.29 | Low : | 1.42 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SCNI ] has closed above bottom band by 25.3%. Bollinger Bands are 1.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.77 - 1.78 | 1.78 - 1.79 |
| Low: | 1.5 - 1.51 | 1.51 - 1.52 |
| Close: | 1.54 - 1.56 | 1.56 - 1.57 |
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.
Mon, 21 Sep 2026
Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement - PR Newswire
Mon, 14 Sep 2026
SCNI Stock Slides As Scinai Refocuses On NanoAb And CDMO - StocksToTrade
Mon, 14 Sep 2026
SCNI Stock Slides As Scinai Refocuses On NanoAb Platform - timothysykes.com
Mon, 14 Sep 2026
Scinai Immunotherapeutics SCNI Shifts Focus To NanoAb Platform - timothysykes.com
Mon, 14 Sep 2026
Scinai Immunotherapeutics SCNI Refocuses On NanoAb And CDMO Growth - StocksToTrade
Wed, 09 Sep 2026
Scinai Immunotherapeutics (SCNI) Edges Higher to $1.71 as Biotech Micro-Cap Holds Key Support - Zero Lag EMA - careplusvn.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 14.1 (%) |
| Held by Institutions | 4.3 (%) |
| Shares Short | 7 (K) |
| Shares Short P.Month | 46 (K) |
| EPS | 28.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 17.35 |
| Profit Margin | -174.8 % |
| Operating Margin | -466.6 % |
| Return on Assets (ttm) | -36.2 % |
| Return on Equity (ttm) | -26.6 % |
| Qtrly Rev. Growth | 146 % |
| Gross Profit (p.s.) | -5.54 |
| Sales Per Share | 2.19 |
| EBITDA (p.s.) | -9.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | 0.05 |
| PEG Ratio | 0 |
| Price to Book value | 0.08 |
| Price to Sales | 0.7 |
| Price to Cash Flow | -0.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|